A Recombinant Oncolytic Influenza Virus Carrying GV1001 Triggers an Antitumor Immune Response.
GV1001
antitumor immune response
cancer
oncolytic virus
rOV-GV1001-NA
Journal
Human gene therapy
ISSN: 1557-7422
Titre abrégé: Hum Gene Ther
Pays: United States
ID NLM: 9008950
Informations de publication
Date de publication:
30 Oct 2023
30 Oct 2023
Historique:
pubmed:
30
8
2023
medline:
30
8
2023
entrez:
30
8
2023
Statut:
aheadofprint
Résumé
Oncolytic viruses are able to lyse tumor cells selectively in the liver without killing normal hepatocytes, in addition to activating the immune response. Oncolytic virus therapy is expected to revolutionize the treatment of liver cancer, including hepatocellular carcinoma (HCC), one of the most frequent and fatal malignancies. In this study, reverse genetics techniques were exploited to load NA fragments of the A/PuertoRico/8/34 virus (PR8) with GV1001 peptides derived from human telomerase reverse transcriptase. An
Identifiants
pubmed: 37646399
doi: 10.1089/hum.2022.206
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM